da Costa Miriane, Ximenes Valdecir Farias, Brunetti Iguatemy Lourenço, Falcão Roberto Passetto, da Fonseca Luiz Marcos
Department of Clinical Analysis (LAC), School of Pharmaceutical Sciences, State University of São Paulo (UNESP), Araraquara, SP, Brazil.
Hematol J. 2004;5(6):496-9. doi: 10.1038/sj.thj.6200562.
In this report, we propose the application of the p-iodophenol-enhanced luminol chemiluminescent technique to the determination of peroxidase (myeloperoxidase and/or platelet peroxidase) activity in blasts of minimally differentiated acute myeloblastic leukemia (AML-M0) and acute megakaryoblastic leukemia (AML-M7).
The frozen blast cells from 29 patients were thawed and submitted to the optimized protocol.
All cases of AML-M7 and AML-M I exhibited integrated light emission greater than 73(10(2) mV x s), which was the arbitrary cutoff point set for the discrimination between AML and acute lymphoblastic leukemia (ALL) (mean + 3 x s.d. of ALL samples, n = 10). In addition, five out of seven cases of AML-MO showed results above the cutoff point.
This highly sensitive enhanced chemiluminescent technique may be applied to discriminate between ALL and AML-M7 or AML-MI cases, and most AML-M0 cases. It is very simple, cheap and easy to perform compared to other procedures used to measure MPO activity in AML-leukemias including AML-M7 and AML-M0.
在本报告中，我们提出将对碘苯酚增强鲁米诺化学发光技术应用于测定微分化急性髓系白血病（AML-M0）和急性巨核细胞白血病（AML-M7）原始细胞中的过氧化物酶（髓过氧化物酶和/或血小板过氧化物酶）活性。
将来自29例患者的冻存原始细胞解冻，并按照优化方案进行处理。
所有AML-M7和AML-M1病例的积分发光均大于73（10(2) mV×s），这是为区分AML与急性淋巴细胞白血病（ALL）所设定的任意临界值（10例ALL样本的均值 + 3×标准差）。此外，7例AML-M0病例中有5例结果高于临界值。
这种高灵敏度的增强化学发光技术可用于区分ALL与AML-M7或AML-M1病例以及大多数AML-M0病例。与用于测量AML白血病（包括AML-M7和AML-M0）中MPO活性的其他方法相比，它非常简单、廉价且易于操作。
